Issue: December 2011
December 01, 2011
2 min read
Save

Drug combination effective for treating uncomplicated malaria in children

The Four Artemisinin-Based Combinations (4ABC) Study Group. PLoS Med. 2011;doi:10.1371/journal.pmed.1001119.

Issue: December 2011
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

A new combination of antimalaria drugs is effective for treating children with uncomplicated malaria, according to results of a new study from Africa.

In a head-to-head comparison of the most currently available artemisinin-based combination therapies in sub-Saharan Africa, the results indicate that artemether-lumefantrine (AL; Coartem, Novartis), amodiaquine-artesunate (ASAQ) and dihydroartemisinin-piperaquine (DHAPQ) had efficacy up to day 63 post-treatment for the treatment of uncomplicated malaria in children aged 6 to 59 months.

Each site compared three of four artemisinin-based combination therapies: ASAQ, DHAPQ, AL or chlorproguanil-dapsone-artesunate (CD+A). The risk of recurrent infections was significantly lower for DHAPQ, followed by ASAQ and then AL. This finding supports the recent recommendation of considering DHAPQ as a valid option for the treatment of uncomplicated Plasmodium falciparum malaria, the researchers said.

From July 2007 to June 2009, a randomized, noninferiority (10% difference threshold in efficacy at day 28) clinical trial was conducted at 12 sites in seven sub-Saharan African countries. Overall, 4,116 children aged 6 to 59 months with uncomplicated P. falciparum malaria were treated (1,226 with AL; 1,002 with ASAQ; 413 with CD+A; and 1,475 with DHAPQ), actively followed up until day 28, and then passively followed up for the next 6 months, according to the study data.

At day 28, for the polymerase chain reaction-adjusted efficacy, noninferiority was established for three pair-wise comparisons: DHAPQ (97.3%) vs. AL (95.5%; OR=0.59; 95% CI, 0.37-0.94); DHAPQ (97.6%) vs. ASAQ (96.8%; OR=0.74; 95% CI, 0.41-1.34); and ASAQ (97.1%) vs. AL (94.4%; OR=0.50; 95% CI, 0.28-0.92).

For the polymerase chain reaction-unadjusted efficacy, AL was significantly less efficacious than DHAPQ and ASAQ, whereas DHAPQ had higher efficacy than ASAQ. However, noninferiority could not be excluded (OR=0.35, 95% CI, 0.26-0.48). CD+A was significantly less efficacious than the other three treatments, and results at day 63 were similar to those observed at day 28.

Disclosure: The project was funded by a grant of the European Developing Countries Clinical Trials Partnership. The Medicine for Malaria Venture (MMV) provided additional funding mainly used for the genotyping of blood samples. The Belgian Directorate-General for Development Cooperation (DGDC) provided support through the framework agreement program between DGCD and the Institute of Tropical Medicine, Antwerp, Belgium.

Twitter Follow InfectiousDiseaseNews.com on Twitter.